Navigation Links
Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetix's Medical Advisory Board
Date:10/9/2007

unctional relationship of abnormalities of the inflammatory process with focus on regulation of phagocytic cells, in the etiology and pathogenesis of periodontal diseases. He is best known for his work on the pathways of resolution of inflammation and pathogenesis of periodontal diseases, neutrophil biology, and clinical research.

"We are very excited to add an individual of Dr. Van Dyke's caliber and experience to our Medical Advisory Board", said Mr. William Spencer, President of Imagenetix. "We believe his joining our Medical Advisory Board validates the success of our periodontal studies at Boston University. We also believe that he will be instrumental in helping us through the FDA process for our periodontal compound 1-TDC which we feel could be a major breakthrough in prevention of periodontal disease."

About Imagenetix

Based in San Diego, California, Imagenetix, (OTC Bulletin Board: IAGX) is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human health on a global basis. Imagenetix develops, formulates and private-labels propriety over-the-counter topical creams, skincare products and nutritional supplements to be marked globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(TM)- Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information, please visit, http://www.imagenetix.net.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those p
'/>"/>

SOURCE Imagenetix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OpGen adds Thomas Pyle and James Ogle to board of directors
2. The birth of biotech: San Francisco, Boston, Geneva or Chicago?
3. Wicab to present BrainPort at Boston conference
4. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
5. Boston entrepreneur to enliven Milwaukee angel group
6. Fermentation Cell Culture: University Style
7. Fueling our economy with the University of Wisconsin
8. CIO Leadership Series: Ed Meachen, University of Wisconsin System
9. University, business leaders convene in Wausau
10. University of South Florida expands GE Healthcare relationship
11. State and university form network for entrepreneurial outreach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against ... were $697 million compared to $701 million in the ... and changes in foreign currency exchange rates decreased sales ... , By business unit, organic sales growth was 6% ... Commercial. , Reported diluted EPS was $0.98 compared ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... BOXMEER, The Netherlands and LONDON, September 26 ,Nobilon ... care business,unit of Akzo Nobel, and Protherics PLC, ... cancer, today announced that Nobilon,has licensed Protherics, CoVaccine ... seasonal influenza vaccines in elderly people. More ...
... Empowers Life Sciences Community with accelerated BioInformatics, ... Corp., announced,the initiation of Progeniq Pte Ltd, ... Singapore, into the BioIT Alliance today. The,BioIT ... integrate science and,technology to accelerate the pace ...
... Tomorrow, Wednesday, September 26th at 8:30am, NEW YORK, ... announced today that it will conduct a conference call,to ... II portfolio,products for a territory outside the US. ... 2007, at,8:30am EDT. Michael S. Weiss, Chairman and CEO ...
Cached Biology Technology:Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications 2Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications 3Progeniq Joins Microsoft in Bio IT Alliance 2Progeniq Joins Microsoft in Bio IT Alliance 3Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance 2
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... diseases are associated with defective proteins accumulating in ... mechanisms are not operating correctly. Now, researchers at ... discovered a molecular link between the cell’s two ... succeeded in using this link to rescue neurodegenerative ...
... Few older people die with brains untouched by a ... signs of dementia increases with the number of different ... new study. The research was funded by the National ... of Health, and conducted at the Rush Alzheimer’s Disease ...
... of the Roche group, and a Yale School of ... company’s Genome Sequencer™ system to identify previously undetectable rare ... performed clinical trial. The work, presented today by ... Medicine and the VA CT Health Care System, was ...
Cached Biology News:Penn researchers link cell's protein recycling systems 2Penn researchers link cell's protein recycling systems 3Study finds mix of disease processes at work in brains of most people with dementia 2454 sequencing identifies HIV drug resistance at early stage 2
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
... is designed to allow neomycin/kanamycin selection ... The loxP-PGK-gb2-neo-loxP template encodes the neomycin/kanamycin ... promoter (gb2) for expression of kanamycin ... promoter (PGK) for expression of neomycin ...
... These precision 5mm diameter, 7 inch long PYREX ... for compatibility with ground joints, valves, and vacuum ... spectrometers running from 300 to 500MHz. They have ... I.D. of 4.20 + 0.013-0.000mm. These NMR tubes ...
Biology Products: